NCT01468233View on ClinicalTrials.gov

Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa

PHASE3CompletedINTERVENTIONAL
Enrollment

326

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Hidradenitis Suppurativa (HS)
Interventions
BIOLOGICAL

adalimumab

Adalimumab pre-filled syringe, administered by subcutaneous injection

BIOLOGICAL

placebo

Placebo pre-filled syringe, administered by subcutaneous injection

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01468233 - Efficacy and Safety Study of Adalimumab in the Treatment of Hidradenitis Suppurativa | Biotech Hunter | Biotech Hunter